Overview

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Varenicline